Digital Health C-Suite Series: Biolinq CEO Rich Yang

Developing the world's first skin-based glucose sensor

Biolinq spent a decade creating one of the smallest electrochemical sensors ever developed and incorporating it into a first-of-its-kind wearable device that continuously detects glucose in the reticular dermis-the bottom layer of the skin.

Tracking glucose levels is one of the main challenges facing diabetic patients. "You have to take a finger stick, draw blood, get a number and then manage your diabetes based on occasional episodic readings." Biolinq's wearable, an investigational device, provides real-time biofeedback, alerting patients when their glucose level rises too high or falls too low, and-crucially-when it's in a healthy target range.

The system also tracks activity levels and sleep, providing context to the patient's metabolic health. "We give you context, all in one disposable, so you don't have to go and find other sources of information with other devices and combine them all on the back end. It's all here in one disposable device."

The Biolinq solution is designed to be the simplest form of sensing for consumers , prescribers and payers, requiring little training to get up and running. "We're architecting this product to be the most ubiquitous plug-and-play bio-wearable."

Read more >